Michelle M. Lebeau to Myelodysplastic Syndromes
This is a "connection" page, showing publications Michelle M. Lebeau has written about Myelodysplastic Syndromes.
Connection Strength
1.773
-
Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527.
Score: 0.479
-
Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model. Blood. 2017 06 01; 129(22):2959-2970.
Score: 0.466
-
Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6.
Score: 0.433
-
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016 10 20; 128(16):2096-2097.
Score: 0.112
-
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
Score: 0.109
-
Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):E6359-68.
Score: 0.106
-
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15; 89(6):2079-88.
Score: 0.029
-
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452.
Score: 0.027
-
Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Exp Hematol. 1995 Oct; 23(11):1160-6.
Score: 0.007
-
Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood. 1993 May 15; 81(10):2728-34.
Score: 0.006